Sandoz continued to strengthen its number one global position in biosimilars (USD 84 million, +28%, +39% cc), and saw strong momentum across all three of its products – Omnitrope (human growth hormone), Binocrit (epoetin alfa) and Zarzio (filgrastim) – each of which is the leading biosimilar in its respective market segment.
Doesn't $84 mil/q seem like a non event at this point?
Market Data 
Markets 
AI
